The terms of engagement (including equity, compensation, role structure) will be tailored to the candidates level of commitment, qualifications, and investment capacity.
Exosome Analytics is a MedTech startup pioneering liquid biopsy innovations. Our solutions enable rapid, non-invasive, and sensitive detection of disease-specific protein markers on exosomes.
Our flagship product is a diagnostic tool for ovarian cancer detection and treatment monitoring, designed for hospitals, cancer centers, and labs. In early trials, it demonstrated over 90% sensitivity at stages I and II, significantly better than current standards (~50%). It also detects pre-cancerous ovarian tumors, allowing for preventive intervention.
Our test is cost-effective and scalable, suitable for widespread screening and post-treatment follow-up. We plan to launch it as a Research Use Only (RUO) tool and prepare for large-scale clinical trials for IVD MD Class B certification.
Our vision is to develop a pan-cancer early detection platform, with promising initial results across other cancer types.
#J-18808-Ljbffr